NexgenRx Inc.
Other OTCTotal Valuation
NexgenRx Inc. carries a market capitalization of 19.20M, placing it among publicly traded companies globally. Its enterprise value stands at 24.27M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 19.20M |
| Enterprise Value | 24.27M |
Share Statistics
NexgenRx Inc. currently has 71.12M shares outstanding.
| Shares Outstanding | 71.12M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
NexgenRx Inc. trades at a trailing price-to-earnings ratio of 13.55. The price-to-sales ratio is 1.47, and the price-to-book ratio stands at 9.74.
| PE Ratio | 13.55 |
| PS Ratio | 1.47 |
| PB Ratio | 9.74 |
| P/TBV Ratio | 5.56 |
| P/FCF Ratio | 5.82 |
| P/OCF Ratio | 5.76 |
Enterprise Valuation
On an enterprise value basis, NexgenRx Inc. trades at an EV/EBITDA multiple of 5.96 and an EV/FCF ratio of 4.84. The EV/Sales ratio of 1.32 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.28 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.32 |
| EV / EBITDA | 5.96 |
| EV / EBIT | 8.28 |
| EV / FCF | 4.84 |
Financial Position
NexgenRx Inc. maintains a current ratio of 1.16, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.93, indicating elevated leverage, while an interest coverage ratio of 167.49 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.16 |
| Quick Ratio | 0.18 |
| Debt / Equity | 3.93 |
| Debt / EBITDA | 0.08 |
| Interest Coverage | 167.49 |
Financial Efficiency
NexgenRx Inc. posts a return on equity of 82.16 and a return on invested capital of 24.88.
| Return on Equity (ROE) | 82.16 |
| Return on Assets (ROA) | 5.42 |
| Return on Invested Capital (ROIC) | 24.88 |
| Return on Capital Employed (ROCE) | 44.65 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, NexgenRx Inc. has paid 645,841.00 in income taxes, reflecting an effective tax rate of 24.49.
| Income Tax | 645,841.00 |
| Effective Tax Rate | 24.49 |
Stock Price Statistics
NexgenRx Inc.'s stock has gained approximately 35% over the past 52 weeks. The 50-day moving average sits at 0.27, while the 200-day moving average is 0.25.
| Beta (5Y) | N/A |
| 52-Week Price Change | 35% |
| 50-Day Moving Average | 0.27 |
| 200-Day Moving Average | 0.25 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, NexgenRx Inc. generated 18.38M in revenue and converted that into 1.99M in net income, yielding earnings per share of 0.03. EBITDA reached 4.07M, while operating income came in at 2.93M.
| Revenue | 18.38M |
| Gross Profit | 15.56M |
| Operating Income | 2.93M |
| Pretax Income | 2.64M |
| Net Income | 1.99M |
| EBITDA | 4.07M |
| EBIT | 2.93M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
NexgenRx Inc. holds 4.71M in cash and equivalents against 346,103.00 in total debt, resulting in a net debt position of -4.71M. Total book value stands at 2.77M, with working capital of 5.05M providing operational flexibility.
| Cash & Cash Equivalents | 4.71M |
| Total Debt | 346,103.00 |
| Net Debt | -4.71M |
| Equity (Book Value) | 2.77M |
| Book Value Per Share | 0.04 |
| Working Capital | 5.05M |
Cash Flow
NexgenRx Inc. produced 4.69M in operating cash flow over the past twelve months. After subtracting -307,123.00 in capital expenditures, free cash flow totaled 4.38M - equivalent to 0.06 per share.
| Operating Cash Flow | 4.69M |
| Capital Expenditures | -307,123.00 |
| Free Cash Flow | 4.38M |
| FCF Per Share | 0.06 |
Margins
NexgenRx Inc. operates with a gross margin of 84.67, reflecting its pricing power and cost economics. The operating margin of 15.95 and net profit margin of 10.83 provide insight into operational efficiency.
| Gross Margin | 84.67 |
| Operating Margin | 15.95 |
| Pretax Margin | 14.35 |
| Profit Margin | 10.83 |
| EBITDA Margin | 22.16 |
Dividends & Yields
The company's payout ratio of 65.19 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.02 |
| Dividend Yield | N/A |
| Payout Ratio | 65.19 |
| Shareholder Yield | 5.19 |
| FCF Yield | 17.19 |
Scores
NexgenRx Inc. posts an Altman Z-Score of 1.35, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.35 |